Tetrabenazine
Tetrabenazine is an approved active ingredient.
Chemical compound
Boxed warning (US label)
Depression and suicidality. DEPRESSION AND SUICIDALITY XENAZINE can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease.
What it is used for
- Tardive dyskinesia
- Huntington's disease
- Tourette syndrome
- Choreic movement
- Congenital torticollis
- Choreatic disease
XENAZINE is indicated for the treatment of chorea associated with Huntington’s disease. XENAZINE is a vesicular monoamine transporter 2 (VMAT) inhibitor indicated for the treatment of chorea associated with Huntington’s disease.
Treatment of moderate to severe tardive dyskinesia in adults.
How it works
- Synaptic vesicular amine transporter inhibitor
Common side effects
The following serious adverse reactions are described below and elsewhere in the labeling: • Depression and Suicidality • Neuroleptic Malignant Syndrome (NMS) • Akathisia, Restlessness, and Agitation • Parkinsonism • Sedation and Somnolence • QTc Prolongation • Hypotension and Orthostatic Hypotension •…
Who should not take it
XENAZINE is contraindicated in patients: • Who are actively suicidal, or in patients with untreated or inadequately treated depression. • With hepatic impairment. • Taking monoamine oxidase inhibitors (MAOIs).
Pregnancy and breastfeeding
There are no adequate data on the developmental risk associated with the use of XENAZINE in pregnant women. Administration of tetrabenazine to rats throughout pregnancy and lactation resulted in an increase in stillbirths and postnatal offspring mortality.
Interactions
- Chlorpromazine — long QT syndrome
- Haloperidol — long QT syndrome
- Hydroxyzine — long QT syndrome
- Methadone — long QT syndrome, torsades de pointes
- Paliperidone — long QT syndrome, torsades de pointes
- Risperidone — long QT syndrome
- Fluoxetine
- Paroxetine
- Quinidine
Brand names
United States
Austedo · Austedo XR · Xenazine
European Union
Austedo
Canada
Apo-Tetrabenazine · Nitoman · Pms-Tetrabenazine
Other trade names
Revocon · Tetmodis · Xenazine 25
Approval status
- US Food and Drug Administration
- prescription · since 2008
- European Medicines Agency
- authorised · since 2026
- Health Canada
- prescription · marketed
- First approval anywhere
- 2008
Codes
- ATC
- N07XX06, N07XX16
- RxNorm CUI
- 10390
- ChEMBL
- CHEMBL117785
- PubChem CID
- 6018
- UNII
- Z9O08YRN8O
- Wikidata
- Q413050
Frequently asked questions
What is Tetrabenazine used for?
Tetrabenazine is used for: Tardive dyskinesia, Huntington's disease, Tourette syndrome, Choreic movement, Congenital torticollis, and Choreatic disease.
What are the brand names of Tetrabenazine?
Brand names of Tetrabenazine include Austedo, Austedo XR, Xenazine, Apo-Tetrabenazine, Nitoman, Pms-Tetrabenazine, Revocon, and Tetmodis.
Medicines in the same class
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)